Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients ============================================================================================================================ * Ilies Benotmane * Gabriela Gautier-Vargas * Noelle Cognard * Jerome Olagne * Francoise Heibel * Laura Braun-Parvez * Jonas Martzloff * Peggy Perrin * Bruno Moulin * Samira Fafi-Kremer * Sophie Caillard ## Abstract Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population. Keyword * kidney transplant recipient * COVID-19 vaccine International recommendations on COVID-19 vaccine distribution have given priority to immunocompromised patients – including kidney transplant recipients (KTRs).1,2 Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti-SARS-CoV-2 antibody response after the first injection. The protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013–1990). We examined 242 KTR who received the first injection of the Moderna mRNA-1273 vaccine (100 µg) at the Strasbourg University Hospital (France) between January 21 and 28, 2021. All had a negative history for COVID-19 and tested negative for anti-SARS-CoV-2 antibodies on the day of the first injection. The anti-SARS-CoV-2 antibody response was assessed at 28 days post-injection using the ARCHITECT IgG II Quant test (Abbott, Abbott Park, IL, USA), with titers >50 AU/mL being considered as positive. One patient developed mild symptomatic COVID-19 seven days after injection and only 26 (10.8%) KTRs had a positive serology at 28 days post-injection. The median IgG titer was 224 AU/mL (interquartile range: 76-496 AU/mL). Patients who seroconverted had longer time from transplantation, received less immunosuppression, and had a better kidney function (Table 1). View this table: [Table 1.](http://medrxiv.org/content/early/2021/03/12/2021.03.08.21252741/T1) Table 1. Characteristics of kidney transplant recipients according to serological response after the first dose of the Moderna mRNA-1273 vaccine In summary, the burden of immunosuppression may induce a weak anti-SARS-CoV-2 antibody response in KTRs after the first injection of an mRNA COVID-19 vaccine. This finding is strikingly different compared with immunocompetent subjects – who invariably seroconverted after the first injection.3,4 We highlight the need not to delay the second vaccine injection in immunocompromised patients. Close surveillance is also recommended to discuss the opportunity of a third dose in less responsive patients. ## Data Availability Data supporting the findings from this study are available from the corresponding author upon reasonable request. * Received March 8, 2021. * Revision received March 8, 2021. * Accepted March 12, 2021. * © 2021, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## References 1. 1.COVID-19 Vaccination Program Operational Guidance | CDC. [https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html](https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html). Accessed March 1st, 2021. 2. 2.ECDC. [https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf). Accessed March 1st, 2021. 3. 3.Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–1931. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F03%2F12%2F2021.03.08.21252741.atom) 4. 4.Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet. 2021;().